SCHEMBL21484636

SCHEMBL21484636

CC(C)(C)c1ccc(-c2csc(NC(=O)/C(C#N)=C/c3ccc(O)c(O)c3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 4/20 0.58
EGFR P00533 7/20 0.52
ERBB2 P04626 6/20 0.52
PTGS2 P35354 1/20 0.52
CSNK2A1 P68400 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 2/20 0.49
RGS12 O14924 2/20 0.49
GMNN O75496 2/20 0.49
LMNA P02545 2/20 0.49
TP53 P04637 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
MAPT P10636 2/20 0.49
ALOX15 P16050 2/20 0.49
ALOX12 P18054 2/20 0.49
NFKB1 P19838 2/20 0.49
MAPK1 P28482 2/20 0.49
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484874 0.94 EGFR (0.51) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21495122 0.91 MRE11 (0.58) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484673 0.91 MRE11 (0.58) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484819 0.90 EGFR (0.54) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484650 0.90 PTGS2 (0.64) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484914 0.88 EGFR (0.56) MRE11EGFRERBB2CSNK2A1MEN1
SCHEMBL21484837 0.88 LMNA (0.54) EGFRERBB2PTGS2CSNK2A1MEN1
SCHEMBL21484888 0.88 EGFR (0.60) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484629 0.88 EGFR (0.62) MRE11EGFRERBB2PTGS2CSNK2A1
SCHEMBL21484889 0.88 EGFR (0.54) EGFRERBB2PTGS2CSNK2A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 MRE11 86/4885EGFR 2905/4885ERBB2 3827/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 MRE11 86/4885EGFR 2905/4885ERBB2 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.